| 1363 |
National Cancer Institute |
Html |
en |
Male Breast Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of male breast cancer. |
| AI vs | 0.370903 |
| mismatch repair mutations | 0.369221 |
| Eggemann et al. | 0.365773 |
| female breast cancer | 0.551031 |
| breast cancer patients. | 0.466631 |
| GnRH analogue | 0.380989 |
| PDQ cancer information | 0.414389 |
| Information About Breast | 0.42794 |
| Preoperative Systemic Therapy | 0.38272 |
| randomized phase | 0.368125 |
| tamoxifen | 0.45543 |
| clinical trial | 0.36672 |
| Intraductal cancer | 0.367134 |
| hormone-releasing hormone | 0.373589 |
| Breast Cancer section | 0.560693 |
| systemic therapy | 0.39727 |
| Postoperative Systemic Therapy | 0.381557 |
| AI therapy | 0.401771 |
| PDQ Adult Treatment | 0.387754 |
| hormonal therapy | 0.380314 |
| retrospective analysis | 0.368006 |
| gonadotropin-releasing hormone | 0.373142 |
| hormone receptor-positive breast | 0.492818 |
| breast cancer. | 0.41194 |
| German Breast Group | 0.488303 |
|
| et al. | 0.433842 |
| Comprehensive Cancer Database | 0.381494 |
| nonpolyposis colorectal cancer | 0.384245 |
| stage breast cancer | 0.454368 |
| Ding et al. | 0.368736 |
| male breast cancer | 0.671805 |
| Lymph node involvement | 0.37157 |
| Early/Localized/Operable Breast Cancer | 0.46567 |
| median follow-up | 0.370308 |
| ductal cancer | 0.367207 |
| Breast Cancer Treatment | 0.527076 |
| PDQ Editorial Boards | 0.382108 |
| pdq summary | 0.467559 |
| adjuvant endocrine therapy | 0.440604 |
| early-stage hormone | 0.372333 |
| breast cancer | 0.962266 |
| adjuvant treatment options | 0.385121 |
| AJCC Stage Groupings | 0.374688 |
| Zagouri et al. | 0.367325 |
| male breast cancers | 0.446407 |
| common tumor type. | 0.372879 |
| specific treatment modalities | 0.365164 |
| analogue versus AI | 0.45406 |
| receptor-positive breast cancer | 0.49928 |
|
CLICK HERE |
| 1397 |
National Cancer Institute |
Html |
en |
Lymphedema (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of lymphedema, a condition in which lymph fluid builds up in tissues and causes swelling. |
| cancer treatment | 0.423589 |
| PDQ cancer information | 0.483377 |
| lymph flow | 0.481362 |
| leg | 0.408261 |
| left lymph duct | 0.48735 |
| white blood cells | 0.398624 |
| secondary lymphedema | 0.507085 |
| clinical trials | 0.422847 |
| cancer information summary | 0.440651 |
| clinical trial | 0.38593 |
| tiny lymph vessels | 0.509598 |
| breast cancer patients | 0.459436 |
| sentinel lymph node | 0.518746 |
| certified lymphedema therapists | 0.498842 |
| breast cancer survivors | 0.394173 |
| upper-body exercise | 0.39564 |
| NCI PDQ cancer | 0.395621 |
| Untreated lymphedema | 0.491735 |
| lymph nodes | 0.686068 |
| swollen area | 0.380684 |
| radiation therapy | 0.378654 |
| treatment | 0.447311 |
| Lymphedema section | 0.47523 |
| lymphedema sleeves | 0.47753 |
| severe lymphedema | 0.470942 |
|
| skin | 0.4219 |
| Cancer Information Service | 0.379239 |
| Primary lymphedema | 0.49612 |
| lymph | 0.792134 |
| body tissues | 0.403337 |
| larger lymph vessels | 0.508148 |
| Stage III lymphedema | 0.489621 |
| National Cancer Institute | 0.439823 |
| arm | 0.413813 |
| lymphedema therapist | 0.534874 |
| Palliative Care Editorial | 0.381473 |
| lymph vessels | 0.714976 |
| limb | 0.427251 |
| lymphedema | 0.932301 |
| certified lymphedema therapist | 0.527418 |
| breast cancer | 0.483638 |
| Care Editorial Board | 0.382648 |
| pressure garment | 0.387805 |
| lymphedema increases | 0.491902 |
| swollen limb | 0.388807 |
| lymph fluid | 0.457795 |
| cancer information summaries | 0.378678 |
| comprehensive cancer information | 0.377712 |
| cancer | 0.547119 |
|
CLICK HERE |
| 1428 |
National Cancer Institute |
Html |
null |
Retinoblastoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of retinoblastoma in children. |
|
|
CLICK HERE |
| 1548 |
National Cancer Institute |
Html |
en |
Breast Cancer Screening (PDQ®)–Patient Version |
Mammogram, clinical breast exam (CBE), and MRI (magnetic resonance imaging) tests are used to screen for breast cancer. Learn about this and other tests that have been studied to detect or screen for breast cancer in this expert-reviewed summary. |
| cancer screening methods | 0.42533 |
| fast-growing breast cancer | 0.440825 |
| ongoing clinical trials | 0.389452 |
| following PDQ summaries | 0.382952 |
| PDQ cancer information | 0.474492 |
| following PDQ summary | 0.39258 |
| breast fluid | 0.391775 |
| common screening test | 0.39988 |
| routine breast cancer | 0.436027 |
| clinical trials | 0.527662 |
| cancer information summary | 0.430839 |
| breast tissue sampling | 0.438767 |
| breast cancer prevention | 0.479726 |
| test results | 0.400913 |
| test | 0.410305 |
| Yearly MRI screening | 0.382239 |
| NCI PDQ cancer | 0.406053 |
| women | 0.476763 |
| PDQ Screening | 0.392324 |
| stage breast cancer | 0.437499 |
| screening tests | 0.377685 |
| breast cancer diagnosis | 0.443317 |
| clinical breast exams | 0.420114 |
| regular breast | 0.389266 |
| Cancer Information Service | 0.377203 |
|
| breast cancers | 0.414043 |
| denser breast tissue | 0.419753 |
| breast duct | 0.396464 |
| breast tissue | 0.495937 |
| Prevention Editorial Board | 0.379673 |
| annual screening mammogram | 0.410065 |
| National Cancer Institute | 0.431327 |
| Cancer Screening Overview | 0.412144 |
| breast cancer benefit | 0.435864 |
| breast biopsy result | 0.412172 |
| lymph vessels | 0.375923 |
| breast tumors | 0.395991 |
| breast cancer screening | 0.602061 |
| Cancer screening trials | 0.429799 |
| clinical breast exam | 0.420394 |
| breast cancer | 0.970368 |
| clinical breast | 0.421091 |
| dense breast tissue | 0.418481 |
| PDQ summary | 0.443066 |
| false-positive screening mammogram | 0.452332 |
| breast self-exams | 0.40904 |
| cancer information summaries | 0.380757 |
| comprehensive cancer information | 0.380439 |
| screening mammogram | 0.469345 |
|
CLICK HERE |
| 1669 |
National Cancer Institute |
Html |
en |
Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood craniopharyngioma |
| evidence | 0.541909 |
| subtotal resection | 0.652496 |
| intensity-modulated photon therapy | 0.593647 |
| Aylwin et al. | 0.579904 |
| Merchant TE | 0.567828 |
| radiation therapy section | 0.596714 |
| PDQ cancer information | 0.54907 |
| Conventional radiation therapy | 0.591705 |
| Tumors Treatment Overview | 0.55265 |
| radiation dose | 0.548781 |
| Int J Radiat | 0.614894 |
| photon radiation therapy | 0.573627 |
| craniopharyngiomas | 0.555197 |
| cancer information summary | 0.541422 |
| Radiat Oncol Biol | 0.7952 |
| irradiated craniopharyngioma | 0.570882 |
| standard fractionated radiation | 0.630603 |
| Tan et al. | 0.575816 |
| conformal radiation treatments | 0.560832 |
| proton therapy | 0.60593 |
| tumor control | 0.588032 |
| common solid tumor | 0.565687 |
| recurrent cystic tumor | 0.550194 |
| radiation therapy | 0.986329 |
| Morisako et al. | 0.5808 |
|
| spare normal tissue | 0.555535 |
| Neurosurg Focus | 0.546254 |
| et al. | 0.839112 |
| complete resection | 0.561879 |
| magnetic resonance imaging | 0.576707 |
| newer radiation technologies | 0.623865 |
| gross-total resection | 0.656285 |
| brain tumor treatment | 0.599377 |
| residual craniopharyngioma | 0.590756 |
| pediatric craniopharyngioma | 0.701375 |
| stereotactic radiation therapy | 0.599058 |
| PUBMED Abstract | 0.577489 |
| craniopharyngioma cyst growth | 0.621968 |
| childhood craniopharyngioma | 0.72734 |
| Abstract | 0.609429 |
| external-beam radiation therapy | 0.569508 |
| pediatric brain tumors | 0.558017 |
| Sterkenburg et al. | 0.578437 |
| Oncol Biol Phys | 0.807866 |
| Neurosurg Pediatr | 0.63126 |
| recurrent craniopharyngioma | 0.572364 |
| papillary craniopharyngioma | 0.570471 |
| tumor | 0.617686 |
| craniopharyngioma | 0.809351 |
|
CLICK HERE |
| 1854 |
National Cancer Institute |
Html |
es |
Tratamiento del melanoma ocular uveal (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del melanoma ocular uveal. |
| Lippincott Williams | 0.0202121 |
| Compton CC | 0.0326793 |
| intraocular melanoma | 0.187253 |
| Singh AD | 0.0183835 |
| mortality findings | 0.0177193 |
| initial mortality findings | 0.0168176 |
| Collaborative Ocular Melanoma | 0.845271 |
| tumores coroideos | 0.0533438 |
| concerning uveal melanomas | 0.0413676 |
| transformation into melanoma | 0.0471527 |
| 7th ed | 0.0334776 |
| melanoma intraocular uveal | 0.0617166 |
| transpupillary thermotherapy | 0.0364759 |
| choroidal melanoma | 0.885011 |
| Ophthalmol Clin | 0.0328664 |
| melanoma coroideo | 0.351056 |
| Radiat Oncol Biol | 0.049169 |
| DeVita VT Jr | 0.0170972 |
| coms report | 0.12083 |
| Iris melanomas | 0.0424181 |
| choroidal melanoma ii | 0.0483613 |
| small choroidal melanoma | 0.146057 |
| from intraocular melanoma | 0.0447667 |
| metastatic melanoma | 0.0397711 |
| Ocular Melanoma Study | 0.837498 |
|
| Shields JA | 0.126368 |
| Diffuse choroidal melanoma | 0.048527 |
| COMS randomized | 0.0359843 |
| melanomas coroideos | 0.0974806 |
| uveal melanomas | 0.9898 |
| Melanoma Study Group | 0.158608 |
| Malignant melanoma | 0.12436 |
| from uveal melanoma | 0.0570651 |
| Cancer Staging Manual | 0.0611746 |
| uveal melanoma management | 0.0496842 |
| COMS Medium Tumor | 0.0243028 |
| Arch Ophthalmol | 0.4179 |
| large choroidal melanoma | 0.0789386 |
| New York | 0.0440447 |
| cLos melanomas | 0.0368816 |
| Diener-West M | 0.0182158 |
| large uveal melanomas | 0.0943176 |
| Oncol Biol Phys | 0.0503576 |
| malignant uveal melanoma | 0.051425 |
| unrecognized choroidal melanoma | 0.0480539 |
| Byrd DR | 0.0304967 |
| Shields CL | 0.154709 |
| Int Ophthalmol Clin | 0.0287474 |
| AJCC Cancer Staging | 0.0646958 |
|
CLICK HERE |
| 2066 |
National Cancer Institute |
Html |
es |
Los cuidados al final de la vida de personas con cáncer |
Hoja informativa que responde algunas de las preguntas que tienen muchos pacientes, sus familiares y quienes cuidan de ellos acerca del final de la vida. |
| desechos quizás | 0.586339 |
| pequeñas porciones | 0.540804 |
| alcance objetos | 0.559532 |
| suficientes glóbulos | 0.562578 |
| causa hinchazón | 0.558057 |
| dosis correctos | 0.546349 |
| médicos cuánto tiempo | 0.63336 |
| suficiente oxÃgeno | 0.652738 |
| cuánto tiempo | 0.903324 |
| suficiente tejido | 0.550065 |
| paciente experimenta sÃntomas | 0.986626 |
| paciente quizás | 0.789052 |
| considerable agitación | 0.540843 |
| quizás querrán | 0.579319 |
|
| menor flujo | 0.542617 |
| presente somnolencia | 0.544492 |
| reducida capacidad | 0.540414 |
| persona enferma causa | 0.731054 |
| malos dÃas | 0.539357 |
| mejores cuidadores | 0.583437 |
| Mayor debilidad | 0.544974 |
| falsas esperanzas | 0.572246 |
| siguientes situaciones | 0.566454 |
| cuerpo boca | 0.542456 |
| familia esté lista | 0.658292 |
| paciente presente incontinencia | 0.756496 |
| persona quizás | 0.668635 |
|
CLICK HERE |
| 15907 |
National Cancer Institute |
Html |
es |
Laetrilo (amigdalina) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer. |
| siguientes teorÃas | 0.410914 |
| suficiente información | 0.405414 |
| Centro Nacional | 0.412476 |
| Phaseolus lunatus | 0.410368 |
| New Hampshire Avenue | 0.408624 |
| Drug Administration | 0.405353 |
| NCI Best Case | 0.416678 |
| fase i | 0.407749 |
| datos bibliográficos pubmed | 0.409348 |
| largo plazo | 0.408034 |
| siguientes preguntas | 0.406283 |
| vitamina b17 | 0.411219 |
| cuáles tipos | 0.408099 |
| vitamina c | 0.408062 |
| vitamina a | 0.409071 |
| siguientes riesgos | 0.407854 |
| seguro médico | 0.405074 |
| Instituto Nacional | 0.512438 |
|
| Salud Complementaria | 0.418716 |
| Visuals Online | 0.406445 |
| siguientes resultados | 0.443523 |
| complementarias revisa | 0.408971 |
| Physician Data Query | 0.437362 |
| siguientes causas | 0.409284 |
| Estados Unidos | 0.980672 |
| enzimas pancreáticas | 0.42962 |
| Corte Suprema | 0.408891 |
| libre uso | 0.407165 |
| determinadas frutas | 0.407416 |
| página manejo | 0.406016 |
| ¿El tratamiento | 0.415719 |
| ¿Los beneficios | 0.405473 |
| juntos cam | 0.405199 |
| Series Program | 0.405225 |
| medicina complementaria | 0.651404 |
|
CLICK HERE |
| 16184 |
National Cancer Institute |
Html |
es |
Manejo de costos y de información médica |
Las personas con cáncer y sus familias pueden enfrentarse a mayores retos económicos. El tratamiento de cáncer puede ser muy caro, aun cuando se tenga seguro. Aprenda cómo mantener la cuenta de tratamientos y de pruebas, de formularios y cobros, y más. |
| cuáles tratamientos | 0.380156 |
| Busque programas | 0.344502 |
| información médica clave. | 0.356222 |
| médico muestras | 0.355273 |
| expediente personal | 0.405493 |
| Health Information Management | 0.361343 |
| importante cuál sistema | 0.365142 |
|
| mayores retos | 0.375386 |
| Busque asistencia | 0.353171 |
| Busque formas | 0.327721 |
| Sociedad Americana | 0.349375 |
| busque ayuda | 0.333405 |
| seguro médico | 0.91222 |
| mano. revise cuáles | 0.413273 |
|
CLICK HERE |
| 16717 |
National Cancer Institute |
Html |
en |
Cancer Clinical Trials at the National Institutes of Health Clinical Center |
Information about cancer clinical trials at the NIH Clinical Center in Bethesda, Maryland. |
| cancer treatment | 0.534356 |
| better understanding | 0.369317 |
| clinical program | 0.414778 |
| eligibility criteria | 0.37194 |
| health insurance | 0.371915 |
| novel cancer treatment | 0.457878 |
| International patients | 0.371646 |
| health care provider | 0.502194 |
| clinical trial experience | 0.462664 |
| clinical teams | 0.407146 |
| NIH physicians | 0.420773 |
| Patients page | 0.377331 |
| NCI clinic | 0.401655 |
| open trials | 0.377021 |
| in-house cancer center | 0.477433 |
| Patient Self-Referral Form | 0.427003 |
| unique hospital | 0.366285 |
| clinical trials | 0.623234 |
| treatment services | 0.380122 |
| health care providers | 0.57596 |
| approach fosters interaction | 0.418119 |
| National Institutes | 0.375152 |
| clinical trial | 0.527278 |
| contact information | 0.370247 |
| CCR clinical trials | 0.482065 |
|
| patients | 0.409802 |
| cancer patients | 0.399962 |
| standard treatment options | 0.440025 |
| trial’s eligibility | 0.38116 |
| related research | 0.378808 |
| patient care units | 0.440886 |
| United States | 0.412623 |
| largest hospital | 0.37768 |
| cancer research | 0.528759 |
| NIH Clinical Center | 0.949828 |
| National Cancer Institute | 0.460111 |
| NCI research team | 0.453825 |
| Clinical Research Referral | 0.467688 |
| Developmental Therapeutics Clinic | 0.698646 |
| advanced cancer | 0.386466 |
| trial information | 0.38805 |
| new treatments | 0.372193 |
| NCI principal investigator | 0.437174 |
| patient treatment plans | 0.430619 |
| compassionate doctors | 0.368527 |
| care specialists | 0.389607 |
| medical care | 0.431584 |
| scientific resources | 0.368533 |
| trial summary | 0.38584 |
|
CLICK HERE |